Advertisement

Antisense Oligo-Mediated Multiple Exon Skipping in a Dog Model of Duchenne Muscular Dystrophy

  • Toshifumi Yokota
  • Eric Hoffman
  • Shin’ichi Takeda
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 709)

Abstract

Exon skipping is currently one of the most promising molecular therapies for Duchenne muscular ­dystrophy (DMD). We have recently developed multiple exon skipping targeting exons 6 and 8 in ­dystrophin mRNA of canine X-linked muscular dystrophy (CXMD), an animal model of DMD, which exhibits severe dystrophic phenotype in skeletal muscles and cardiac muscle. We have induced efficient exon skipping both in vitro and in vivo by using cocktail antisense 2’O-methyl oligonucleotides (2’OMePS) and cocktail phosphorodiamidate morpholino oligomers (morpholinos, or PMOs) and ameliorated phenotype of dystrophic dogs by systemic injections. The multiple exon skipping (double exon skipping) shown here provides the prospect of choosing deletions that optimize the functionality of the truncated dystrophin protein for DMD patients by using a common cocktail that could be validated as a single drug and also potentially applicable for more than 90% of DMD patients.

Key words

Multiple exon skipping Morpholinos (phosphorodiamidate morpholino oligomers) O-methylated antisense oligomers (phosphorothioate) Dystrophic dogs (canine X-linked muscular dystrophy) Duchenne/Becker muscular dystrophies 

Notes

Acknowledgments

Authors thank Drs. Terence Partridge, Stephanie Duguez (Children’s National Medical Center, Washington DC), Masanori Kobayashi, Yoshitsugu Aoki, Takashi Saito, Katsutoshi Yuasa, Naoko Yugeta, Sachiko Ohshima, Jin-Hong Shin, Michiko Wada, Kazuhiro Fukushima, Satoru Masuda, Kazue Kinoshita, Hideki Kita, Shin-ichi Ichikawa, Yumiko Yahata, Takayuki Nakayama, Akinori Nakamura (National Institute of Neuroscience, Tokyo, Japan), Adam Rabinowitz, and Jonathan Beauchamp (Imperial College, London, UK), Qi-long Lu (Carolinas Medical Center) for discussions and technical assistance. This work was supported by the Foundation to Eradicate Duchenne, the Department of Defense CDMRP program, the Jain Foundation, the Crystal Ball of Virginia Beach (Muscular Dystrophy Association USA), the National Center for Medical Rehabilitation Research, the NIH Wellstone Muscular Dystrophy Research Centers, and the Ministry of Health, Labor, and Welfare of Japan (Research on Nervous and Mental Disorders, 16B-2, 19A-7; Health and Labor Sciences, Research Grants for Translation Research, H19-translational research-003, Health Sciences Research Grants Research on Psychiatry and Neurological Disease and Mental Health, H18-kokoro-019).

References

  1. 1.
    Hoffman, E. P., Brown, R. H., Jr., and Kunkel, L. M. (1987) Dystrophin: the ­protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928.PubMedCrossRefGoogle Scholar
  2. 2.
    Yokota, T., Duddy, W., and Partridge, T. (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26, 179–184.PubMedGoogle Scholar
  3. 3.
    Yokota, T., Takeda, S., Lu, Q. L., Partridge, T. A., Nakamura, A., and Hoffman, E. P. (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66, 32–38.PubMedCrossRefGoogle Scholar
  4. 4.
    Yokota, T., Pistilli, E., Duddy, W., and Nagaraju, K. (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 7, 831–842.PubMedCrossRefGoogle Scholar
  5. 5.
    Yokota, T., Lu, Q. L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., and Hoffman, E. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65, 667–676.PubMedCrossRefGoogle Scholar
  6. 6.
    Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., and Partridge, T. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102, 198–203.PubMedCrossRefGoogle Scholar
  7. 7.
    Shimatsu, Y., Katagiri, K., Furuta, T., Nakura, M., Tanioka, Y., Yuasa, K., Tomohiro, M., Kornegay, J. N., Nonaka, I., and Takeda, S. (2003) Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52, 93-97.PubMedCrossRefGoogle Scholar
  8. 8.
    Sharp, N. J., Kornegay, J. N., Van Camp, S. D., Herbstreith, M. H., Secore, S. L., Kettle, S., Hung, W. Y., Constantinou, C. D., Dykstra, M. J., Roses, A. D., and et al. (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13, 115–121.PubMedCrossRefGoogle Scholar
  9. 9.
    Ham, R. G. (1963) An improved nutrient solution for diploid Chinese hamster and human cell lines. Exp Cell Res 29, 515–526.PubMedCrossRefGoogle Scholar
  10. 10.
    Jankowski, R. J., Haluszczak, C., Trucco, M., and Huard, J. (2001) Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: potential for rapid isolation of muscle-derived stem cells. Hum Gene Ther 12, 619–628.PubMedCrossRefGoogle Scholar
  11. 11.
    Yokota, T., Lu, Q. L., Morgan, J. E., Davies, K. E., Fisher, R., Takeda, S., and Partridge, T. A. (2006) Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J Cell Sci 119, 2679–2687.PubMedCrossRefGoogle Scholar
  12. 12.
    Shimatsu, Y., Yoshimura, M., Yuasa, K., Urasawa, N., Tomohiro, M., Nakura, M., Tanigawa, M., Nakamura, A., and Takeda, S. (2005) Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24, 145–154.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Toshifumi Yokota
    • 1
  • Eric Hoffman
    • 1
  • Shin’ichi Takeda
    • 2
  1. 1.Research Center for Genetic MedicineChildren’s National Medical CenterWashingtonUSA
  2. 2.Department of Molecular Therapy, National Institute of NeuroscienceNational Center of Neurology and Psychiatry (NCNP)TokyoJapan

Personalised recommendations